Bristol-Myers Squibb Co
XMUN:BRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bristol-Myers Squibb Co
XMUN:BRM
|
US |
|
B
|
Brown & Brown Inc
XMUN:BTW
|
US |
|
O
|
Otis Worldwide Corp
F:4PG
|
US |
|
H
|
Hacksaw AB
STO:HACK
|
SE |
Intrinsic Value
Is BRM undervalued or overvalued?
See the intrinsic value estimate for 
Bristol-Myers Squibb Co and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
BRM looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with BRM’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Bristol-Myers Squibb Does
Bristol-Myers Squibb is a global drugmaker that develops, manufactures, and sells prescription medicines for serious diseases. Its products are used mainly in cancer, heart disease, immune disorders, and blood diseases. The company spends heavily on research, clinical trials, and regulatory approval because its business depends on turning scientific discoveries into approved medicines.
- Headquarters
- United States of America US
- Employees
- 32 500
- IPO date
- Mar 17, 1980
Bristol-Myers Squibb has a wide economic moat
Patents and legal protection against copies prevent rivals from freely reproducing Bristol Myers Squibb’s protected medicines and competing mainly on price. These protections cover a broad range of treatments, including cancer drugs and medicines for heart and immune conditions, rather than depending on a single discovery.
Read the full moat analysis
Revenue & Expenses Breakdown
Bristol-Myers Squibb Co
Earnings Waterfall
Bristol-Myers Squibb Co
The intrinsic value for Bristol-Myers Squibb Co (BRM) under the Base Case is hidden EUR.
Compared with the current market price of 54.55 EUR, the stock appears hidden.